Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Nubeqa
Pharma
Bayer charts growth course amid Xarelto's ongoing sales descent
The company plans to keep building out blockbuster hopeful Nubeqa, popular Eyelea and newer Kerendia as its top-selling Xarelto succumbs to generics.
Zoey Becker
Aug 6, 2024 12:29pm
Bayer clinches 2nd win for Nubeqa in prostate cancer subtype
Jul 17, 2024 9:42am
Bayer pharma commercial boss talks restructuring, oncology goals
Jul 10, 2024 9:36am
Bayer de-emphasizes the impact of Roche's Vabysmo on Eylea sales
May 14, 2024 11:46am
Bayer's new CEO Bill Anderson weighs structural change
Aug 8, 2023 11:15am
Bayer needs acquisition to meet oncology sales goal, exec says
Jun 12, 2023 2:19pm
